Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients Receiving 5-HT3-RA Therapy throughout Chemotherapy Cycles

VBCC - March 2013, Volume 4, No 3 - AVBCC 2013 3rd Annual Conference Abstracts
Faria C
Nagl N
Powers A. Eisai, Inc. 100 Tice Blvd. Woodcliff Lake, NJ 07667

Objective: Current guidelines support the use of 5-HT3-RAs for chemotherapy-induced nausea and vomiting (CINV). Controlling CINV upon chemotherapy initiation is important as the likelihood of CINV in future chemotherapy cycles increases if a patient experiences CINV in the first/previous chemotherapy cycle. The purpose of this study was to evaluate the overall rate of CINV, and compare the odds of CINV per chemotherapy cycle in patients with lung cancer receiving the same 5-HT3-RA throughout chemotherapy cycles.

Methods: A retrospective database analysis was conducted utilizing medical and pharmacy claims from 2005-2011 in a commercial (96%) and Medicaid (4%) population. Continuously enrolled patients (6 month pre-period, 6 month post-period) with a diagnosis of lung cancer receiving single-day chemotherapy regimens were eligible. Patients were required to remain on the initial 5-HT3-RA therapy and same level of emetic potential of chemotherapy throughout. CINV was defined as a primary or secondary diagnosis of nausea, vomiting, or dehydration or use of rescue antiemetic medication. Overall rates of CINV were calculated, and odds for CINV for each chemotherapy cycle were calculated by 5-HT3-RA agent. Patients without CINV in the previous cycle or who switched 5-HT3-RA therapy were excluded from subsequent calculations.

Results: A total of 3,863 patients were included in the analysis. Average age was 61 years, and mean Charlson Comorbidity score was 5.3. The overall CINV rate regardless of 5-HT3-RA was 17% at Cycle 1, and more than doubled for Cycle 2 and Cycle 3 (39.0% and 71.8%, respectively). Multivariate analysis showed patients receiving ondansetron, granisetron, or dolasetron had significantly higher odds of developing CINV at Cycle 2 vs palonosetron (Cycle 2 OR: 2.02; 95% CI: 1.23, 3.32 for ondansetron, OR: 2.79; 95% CI: 1.73, 4.49 for granisetron, OR: 1.85; 95% CI: 1.03, 3.32 for dolasetron; p<0.05 for all comparisons) and significantly higher odds for ondansetron and granisetron vs palonosetron at Cycle 3 (Cycle 3 OR: 3.36; 95% CI: 1.22, 9.24 for ondansetron, OR: 2.65; 95% CI: 1.07, 6.57 for granisetron; p<0.05 for each).

Conclusions: CINV rates increased in subsequent chemotherapy cycles for patients who experienced CINV and maintained therapy with the same 5-HT3-RA. For patients receiving palonosetron, the odds of experiencing CINV in subsequent cycles was lower than patients receiving one of the other 5-HT3-RAs.

Related Items
Perspectives of Quality Care in Cancer Treatment: A Review of the Literature
Lisa M. Hess, PhD, Gerhardt Pohl, PhD
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Is Oral Electrolyte Replacement More Effective than IV Replacement in the Oncology Population?
Rebecca Martin, BSN, RN, OCN, Joanne Growney, RN, MA, ANP-BC
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Cost Considerations for New Oral Therapies for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously
Lorie A. Ellis, Zoe Clancy, R. Scott McKenzie, Mekre’ Senbetta
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Cost Analysis of Bortezomib Retreatment Compared with Switching to Carfilzomib in Patients with Relapsed Multiple Myeloma Previously Treated with Bortezomib
Kevin B. Knopf, MD, MPH, Marie-Hélène Lafeuille, MA, Jonathan Gravel, MS, Patrick Lefebvre, MA, Liviu Niculescu, MD, Abbie Ba-Mancini, MBA, Esprit Ma, MPH, Mei Sheng Duh, MPH, ScD
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Imatinib Can Still Be Used as 1st-Line for Treating Chronic Myelogenous Leukemia
Wesley Wong, PhD
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Wait Time and Patient Satisfaction—Improving Outcomes Can Be as Easy as Child’s Play
Julia Whiteker, Ann Bredensteiner
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Say Ahh! Making Sense of Oral Assessments for Mucositis
Joanne Growney, MA, RN, ANP-BC, OCN, Rebecca Martin, BSN, RN, OCN, Phyllis McKiernan, RN, MSN, APN-BC, Joan Collela, RN, DNP, APN-BC, NP-C, Claudia Douglas, RN, MA, CNN, APN-C
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Impact of Granulocyte Colony-Stimulating Factor and Treatment Modification on Eribulin Mesylate Therapy in Metastatic Breast Cancer Patients with Neutropenia
Gluck S, Yardley D, Belk K, Craver C, Cox D, Faria C, University of Miami, Leonard M. Miller School of Medicine, Miami, FL; Tennessee Oncology, PLLC, Nashville, TN; MedAssets, Inc., Charlotte, NC; Eisai Inc., Woodcliff Lake, NJ
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Impact of Treatment Modification on Treatment Duration in Metastatic Breast Cancer Patients Treated with Eribulin Mesylate
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
An Assessment of Racial Differences in Toxicities and Supportive Care in Patients with Metastatic Breast Cancer (MBC)
George Dranitsaris, Nancy Beegle, Traci Kalberer, Zhixiao Wang, Claudio Faria, Sibel Blau
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Last modified: May 28, 2014
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology